Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs DENTSPLY SIRONA Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while DENTSPLY SIRONA Inc trades at $11.46 (market cap $2.31B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 12.8× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | XRAY | |
|---|---|---|
Market Cap | $29.60B | $2.31B |
Sector | Health | Health |
52-Week High | $491.22 | $14.68 |
52-Week Low | $205.48 | $9.64 |
Enterprise Value | $27.56B | $4.39B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
DENTSPLY SIRONA (XRAY) trades at $11.32, down 2.92% today, with a bearish technical signal and mixed fundamentals. The company reported Q2 2026 EPS of $0.52, beating expectations, but revenue declined 4.1% year-over-year. Net income remains negative, though margins show improvement. The stock is near its consensus price target of $11.50, with support at $11 and resistance at $12.
Outlook is cautious; while cost controls and new partnerships offer potential, persistent revenue declines and high debt levels pose significant risks. Analyst sentiment is predominantly Hold, reflecting uncertainty around the turnaround plan's success amid weak dental market demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
